SequelSEC

Neumora Therapeutics, Inc. NMRA

Biological Products, (No Diagnostic Substances) · CIK 0001885522 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$241.16M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Neumora Therapeutics, Inc. (NMRA) reported net income of -$236.93M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Neumora Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Neumora Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
RevenueUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$241.16M-$263.46M-$252.10M-$135.87M
Net income-$236.93M-$243.79M-$235.92M-$130.90M
Research & development$176.06M$200.93M$142.72M$91.75M
Weighted-average diluted sharesshares 163.39Mshares 159.38Mshares 65.02Mshares 27.21M
Pretax income-$236.80M-$243.61M-$235.66M-$130.90M
Income tax expense$130.00K$178.00K$268.00KUnavailable
Diluted EPS$-1.45$-1.53$-3.63$-4.81
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$60.09M$62.54M$45.48M$31.12M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Neumora Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Cash & equivalents$182.53M$142.15M$374.04M$240.94M
Total assets$191.05M$316.97M$496.20M$426.23M
Current assets$190.54M$314.06M$478.28M$387.96M
Total liabilities$87.18M$29.91M$27.12M$29.40M
Current liabilities$32.45M$29.89M$25.11M$23.70M
Total equity incl. NCI$103.87M$287.06M$469.08M-$446.85M
Temporary (mezzanine) equityUnavailableUnavailableUnavailable$843.69M
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debt$54.53M$0UnavailableUnavailable
Accounts payable$3.38M$3.31M$337.00K$7.15M

Cash flow

Neumora Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Operating cash flow-$206.44M-$182.94M-$163.28M-$114.90M
Capital expendituresUnavailableUnavailable$117.00K$511.00K
Investing cash flow$168.52M-$70.56M$64.39M-$168.01M
Financing cash flow$77.09M$21.60M$231.94M$115.74M
Net change in cash$39.17M-$231.89M$133.04M-$167.17M
Stock-based compensation$29.88M$39.99M$17.24M$8.30M
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$208.00K$631.00K$668.00K$594.00K

Derived

Neumora Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Free cash flowUnavailableUnavailable-$163.40M-$115.41M
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable
Current ratio5.87x10.51x19.05x16.37x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable
Long-term debt / equity0.52xUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NMRA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.